Nanobiotix (NBTX) Receivables - Other (2019 - 2025)

Nanobiotix (NBTX) has 7 years of Receivables - Other data on file, last reported at $1.7 million in Q4 2025.

• In Q4 2025, Receivables - Other fell 47.77% year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $1.7 million (down 47.77% YoY), while the FY2025 annual figure was $1.6 million, down 49.95% from the prior year.
• Receivables - Other retreated to $1.7 million in Q4 2025, from $3.2 million in the prior quarter.
• Across five years, Receivables - Other topped out at $3.9 million in Q4 2021 and bottomed at $1.5 million in Q4 2023.
• A 5-year average of $2.6 million and a median of $2.8 million in 2022 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2021 — Receivables - Other soared 252.29% — and 2025, when it tumbled 47.77%.
• Year by year, Receivables - Other stood at $3.9 million in 2021, then dropped by 27.63% to $2.8 million in 2022, then tumbled by 45.44% to $1.5 million in 2023, then surged by 108.3% to $3.2 million in 2024, then slumped by 47.77% to $1.7 million in 2025.
• The last three Receivables - Other figures came in at $1.7 million (Q4 2025), $3.2 million (Q4 2024), and $1.5 million (Q4 2023), per Business Quant data.

Peer Comparison